Tirzepatide dose escalation and appetite suppression: what week 5 really means

What's this video probably claiming?

Based on the caption, @less_of_lesley is documenting week five of a tirzepatide journey, having just escalated from a lower starting dose to 5mg. The video likely shows a "what I eat in a day" style log, with the creator struggling to hit adequate calorie intake because appetite suppression is hitting hard. The implicit message, reinforced by the question "what do you eat on high suppression days?", is that severe appetite reduction at dose escalation is normal, expected, and something to troubleshoot with food choices rather than medical guidance. There's also an embedded assumption that eating less is the goal, with low intake framed as a minor inconvenience to manage rather than a potential clinical concern. These are claims worth examining carefully, because the GLP-1 community on TikTok has developed its own folk wisdom around appetite suppression that doesn't always match what the trial data actually shows about nutrition adequacy on these medications.

What does the science actually show?

Tirzepatide's appetite suppression is real and well-documented. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that participants on 15mg tirzepatide lost a mean of 20.9% of body weight over 72 weeks. But here's what gets glossed over in the content creator version: the trial participants were eating structured, dietitian-monitored diets with a 500 kcal daily deficit. They weren't winging it. Dose escalation to 5mg is typically weeks four through eight of the standard titration schedule, and GI side effects, including nausea, early satiety, and reduced appetite, do tend to peak around dose changes. A 2023 analysis in Obesity (Wadden et al.) noted that protein intake specifically can fall to inadequate levels during GLP-1 therapy, accelerating lean muscle loss. Eating too little isn't a badge of honor. It's a risk factor for losing the wrong kind of weight.

Where does the social media noise diverge from clinical reality?

The TikTok tirzepatide community has built an entire subculture around "suppression days" as positive events, almost competitive markers of how well the drug is working. That framing is problematic for several reasons. First, severe appetite suppression is a side effect to manage, not a target. Eli Lilly's prescribing information for Mounjaro explicitly lists decreased appetite as an adverse reaction, not a therapeutic endpoint. Second, the crowd-sourced advice about what to eat on high suppression days, typically soft foods, small portions, or in some cases almost nothing, rarely accounts for protein targets. Research from Bikou et al. (2023, Nutrients) found GLP-1 users commonly under-consume protein during active weight loss phases, which matters because muscle loss accounts for a disproportionate share of total weight lost when calories drop too low without resistance training. Third, no one in these comment sections is asking whether the creator has spoken to a clinician about struggling to consume food. That's a gap.

What should you actually know?

If you're on tirzepatide and struggling to eat on dose escalation weeks, a few things are worth knowing. Appetite suppression severe enough to prevent adequate intake is worth flagging to whoever prescribed your medication. It may mean the titration schedule needs adjusting. The standard recommendation from obesity medicine clinicians is to prioritise protein, aiming for roughly 1.2 to 1.6 grams per kilogram of body weight daily, even on low-appetite days. A 2022 paper in Current Obesity Reports (Apovian et al.) argued this range helps preserve lean mass during GLP-1-driven weight loss. Calorie targets matter too. Dropping below roughly 1,000 to 1,200 kcal per day for extended periods risks nutrient deficiencies and metabolic adaptation. The goal of tirzepatide is sustainable fat loss, not maximum suppression. Community tips from TikTok are not a substitute for structured dietary support, and the evidence suggests most people on these medications benefit significantly from working with a registered dietitian alongside their prescriber.